Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2020, 45(3): 153
ISSN 0377-8282
e-ISSN 2013-0368
Copyright 2020 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2020.45.3.3098155
Centhaquine citrate. alpha2B-Adrenoceptor ligand, Resuscitative agent for hypovolemic shock
Gulati, A., Lavhale, M., Giri, R., Andurkar, S.V., Xanthos, T.
Hypovolemic shock is a serious, unmet, life-threatening medical condition with high mortality that results from excessive blood loss leading to inadequate tissue perfusion and oxygenation. Immediate medical attention is required because a delay in therapy can lead to irreversible shock, multiorgan failure and death. We demonstrated that centhaquine is a first-in-class, safe and highly effective resuscitative agent for the treatment of hypovolemic shock. It acts on alpha2B-adrenergic receptors to produce venous constriction and increase venous return to the heart, resulting in an increase in cardiac output and improved tissue perfusion. Centhaquine also acts on central alpha2A-adrenergic receptors to reduce sympathetic drive and decrease systemic vascular resistance contributing to an improved tissue blood perfusion. Pharmazz Inc. has successfully completed preclinical and clinical studies. Centhaquine has a high safety margin and significantly improves mortality, blood pressure and blood lactate levels compared with standard of care.

Full Text: PDF 

© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences